Fingers, I can't understand much of what you said there,...

Fingers, I can't understand much of what you said there, however, in terms of what possible partners would be looking for from BIT225 in HCV treatment, these would include (in order of importance):
1) synergy with probably a NS5b inhibitor against G3 HCV
2) low toxicity to allow use across all patients groups
3) no significant drug-drug interactions
4) ability to be formulated into a once daily pill with probably a NS5a and NS5b inhibitor
At this stage none of these properties have been demonstrated. The most important, 1), requires an expensive trial that will probably only occur after an IND application so it can be undertaken in the US (as Americans have low regard for trials not carried out in the US), and will likely require a further capital raising. This latest trial will address 2) to a large extent, and as I have commented already there is a concerning signal that toxicity may be a significant issue.
If you think that there is a queue of pharmaceutical companies about to leap into partnership with Biotron at the current time then you are living in a dreamworld.